Last reviewed · How we verify
Euvichol
Euvichol is a Biologic drug developed by EuBiologics Co.,Ltd. It is currently in Phase 3 development. Also known as: Oral Cholerae Vaccine.
-
Baseline phase 3 → approval rate
+58.3pp
Industry-wide phase 3 drugs reach approval ~58.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2028–2030 | — |
| EMA | EU | 2029–2031 | +0.7 yr |
| MHRA | GB | 2029–2031 | +0.7 yr |
| Health Canada | CA | 2029–2032 | +0.9 yr |
| TGA | AU | 2029–2032 | +1.2 yr |
| PMDA | JP | 2029–2032 | +1.5 yr |
| NMPA | CN | 2030–2033 | +2.3 yr |
| MFDS | KR | 2029–2032 | +1.4 yr |
| CDSCO | IN | 2029–2033 | +1.8 yr |
| ANVISA | BR | 2030–2033 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | Euvichol |
|---|---|
| Also known as | Oral Cholerae Vaccine |
| Sponsor | EuBiologics Co.,Ltd |
| Modality | Biologic |
| Therapeutic area | Other |
| Phase | Phase 3 |
Approved indications
Common side effects
Key clinical trials
- Extended Dosing Intervals Trial for Oral Cholera Vaccine, Kenya (PHASE4)
- Trial to Evaluate Immunogenicity Non-Inferiority, Safety and Lot-to-Lot Consistency of Biovac OCV-S to Euvichol®-Plus (PHASE3)
- Immune Response to a Delayed Second Dose of Oral Cholera Vaccine (PHASE4)
- Safety and Immunogenicity of a New Formulation of Euvichol® (PHASE3)
- To Evaluate the Efficacy (Immunogenicity) and Safety of Euvichol in Healthy Adults and Children (PHASE3)
- To Determine the Safety and Immunogenicity of an Oral(Whole Cell) Euvichol Cholera Vaccine in Healthy Adult Men (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Euvichol CI brief — competitive landscape report
- Euvichol updates RSS · CI watch RSS
- EuBiologics Co.,Ltd portfolio CI
Frequently asked questions about Euvichol
What is Euvichol?
Who makes Euvichol?
Is Euvichol also known as anything else?
What development phase is Euvichol in?
Related
- Manufacturer: EuBiologics Co.,Ltd — full pipeline
- Therapeutic area: All drugs in Other
- Also known as: Oral Cholerae Vaccine
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing